Parmax Pharma
Parmax Pharma (PARMAX) share price was ₹135.05 at the 26 Oct 2026 close; market capitalisation ₹92.94 Cr; sector Healthcare. The share price rose 286.0% over the year to 26 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue was ₹8.22 Cr, against ₹1.94 Cr a year earlier and net profit was ₹2.20 Cr, against −₹0.76 Cr a year earlier (compared with Jun 2025). Promoters held 64.66% of Parmax Pharma in Sep 2026, up 33.86 percentage points from Jun 2026. Its Tapetide Score is 40/100 (Weak) as of 28 Oct 2026.
Key Fundamentals
MicrocapPharmaceuticalsHealthcarePrice-based figures as of 28 Oct 2026, 16:30 IST · EPS basis: Standalone · TTM
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,766.00 | 35.03 | 4,23,723 Cr | 5.07 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,637.50 | 87.47 | 2,55,845 Cr | 15.26 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,598.40 | 72.19 | 1,74,908 Cr | 9.52 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,184.50 | 107.93 | 1,18,031 Cr | 22.27 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,180.50 | 26.27 | 1,17,755 Cr | 4.34 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,341.20 | 34.74 | 1,11,947 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,370.10 | 32.82 | 1,10,685 Cr | 3.13 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Parmax Pharma (this company) | ₹135.05 | — | 93 Cr | 20.22 | 0.00% | 67.65% | -85.76% | 20 Cr | -1 Cr |
| Median 8 companies | ₹1,568.05 | 35.03 | 1,17,893 Cr | 7.30 | 0.47% | 14.56% | 16.41% | 22,787 Cr | 3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 86/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is expected to give good quarter
- Promoter holding has increased by 33.9% over last quarter.
Weaknesses
3- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -14.3% over past five years.
- Debtor days have increased from 57.4 to 95.2 days.
Technical Indicators
Oscillators
Bearish
Overall
Bullish
Moving Averages
Bullish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
Operating margin 10.1% · Jun 2026
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.4 | 4.07 | 1.33 | 4.26 | 7.82 | 9.28 | 6.28 | 4.83 | 1.94 | 2.53 | 4.33 | 3.31 | 8.22 |
| Expenses | 2.05 | 4.84 | 2.48 | 5.06 | 7.31 | 9.08 | 6.17 | 5.39 | 2.19 | 4.12 | 4.53 | 4.86 | 7.39 |
| Operating Profit | -0.65 | -0.77 | -1.15 | -0.8 | 0.51 | 0.2 | 0.11 | -0.56 | -0.25 | -1.59 | -0.2 | -1.55 | 0.83 |
| OPM % | -46.43% | -18.92% | -86.47% | -18.78% | 6.52% | 2.16% | 1.75% | -11.59% | -12.89% | -62.85% | -4.62% | -46.83% | 10.1% |
| Other Income | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.12 | 0.01 | -1.17 | 0.01 | 0.01 | 0.01 | 0.03 | 2.08 |
| Interest | 0.12 | 0.18 | 0.16 | 0.16 | 0.11 | 0.13 | 0.11 | 0.24 | 0.28 | 0.24 | 0.28 | 0.5 | 0.23 |
| Depreciation | 0.42 | 0.43 | 0.45 | 0.41 | 0.4 | 0.4 | 0.41 | -0.18 | 0.24 | 0.26 | 0.27 | 0.25 | 0.48 |
| PBT | -1.18 | -1.37 | -1.75 | -1.36 | 0.01 | -0.21 | -0.4 | -1.79 | -0.76 | -2.08 | -0.74 | -2.27 | 2.2 |
| Tax % | 0% | 0% | 0% | 6.62% | 0% | 0% | 0% | -16.76% | 0% | 0% | 0% | -74.45% | 0% |
| Net Profit | -1.18 | -1.37 | -1.75 | -1.45 | 0.01 | -0.22 | -0.39 | -1.49 | -0.76 | -2.08 | -0.73 | -0.58 | 2.2 |
| EPS (₹) | -3.15 | -3.66 | -4.68 | -3.88 | 0.03 | -0.59 | -1.04 | -3.98 | -2.03 | -5.56 | -1.95 | -1.55 | 5.88 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 11.89 | 11.99 | 20.92 | 26.17 | 18.24 | 15.39 | 11.02 | 28.2 | 12.11 | 18.39 |
| Expenses | 0.02 | 0.05 | 0.05 | 10.81 | 10.88 | 19.15 | 22.74 | 15.67 | 13.14 | 14.39 | 27.94 | 15.75 | 20.9 |
| Operating Profit | -0.02 | -0.05 | -0.05 | 1.08 | 1.11 | 1.77 | 3.43 | 2.57 | 2.25 | -3.37 | 0.26 | -3.64 | -2.51 |
| OPM % | — | — | — | 9.08% | 9.26% | 8.46% | 13.11% | 14.09% | 14.62% | -30.58% | 0.92% | -30.06% | -13.65% |
| Other Income | 0.06 | 0.06 | 0.06 | 0.05 | 0.05 | 0.1 | 0.09 | 0.06 | 0.04 | 0.05 | -1.03 | 0.05 | 2.13 |
| Interest | 0 | 0 | 0 | 0.04 | 0.03 | 0.13 | 0.37 | 0.39 | 0.37 | 0.62 | 0.59 | 1.24 | 1.25 |
| Depreciation | 0 | 0 | 0 | 1.09 | 1.03 | 1.01 | 1.94 | 1.93 | 1.88 | 1.71 | 1.03 | 1.01 | 1.26 |
| PBT | 0.04 | 0.01 | 0.01 | 0 | 0.1 | 0.73 | 1.21 | 0.31 | 0.04 | -5.65 | -2.39 | -5.84 | -2.89 |
| Tax % | 25% | 200% | 100% | — | 20% | 41.1% | 38.02% | 54.84% | 375% | 1.77% | -12.55% | -28.94% | — |
| Net Profit | 0.02 | 0 | -0.01 | 0 | 0.08 | 0.43 | 0.75 | 0.14 | -0.1 | -5.75 | -2.09 | -4.16 | -1.19 |
| EPS (₹) | 0.05 | 0 | -0.03 | 0 | 0.21 | 1.15 | 2 | 0.37 | -0.27 | -15.37 | -5.59 | -11.12 | -3.18 |
| Div. Payout % | 0% | — | 0% | — | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.03 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 |
| Reserves | 0.12 | 0.11 | 0.1 | 0.11 | 0.18 | 0.61 | 1.37 | 1.51 | 1.4 | -4.35 | -6.44 | -10.6 |
| Borrowings | 0.79 | 0.46 | 1.02 | 1.96 | 5.52 | 5.26 | 5.89 | 5.18 | 5.37 | 5.91 | 8.09 | 12.06 |
| Other Liabilities | 0.04 | 0.06 | 2.14 | 10.11 | 9.56 | 10.75 | 11.01 | 6.83 | 6.39 | 9.32 | 12.65 | 22.14 |
| Total Liabilities | 4.98 | 5.08 | 7.71 | 16.63 | 19.71 | 21.07 | 22.72 | 17.97 | 17.61 | 15.33 | 18.75 | 28.05 |
| Fixed Assets | 2.53 | 2.53 | 2.72 | 5.86 | 4.92 | 9.64 | 10.84 | 10.44 | 9.5 | 9.27 | 7.97 | 7.86 |
| CWIP | 0 | 0 | 0 | 0 | 3.33 | 0 | 0 | 0 | 0 | 0.1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0.2 | 0.2 | 0.2 | 0 | 0 | 0 | 0.4 | 0.4 |
| Other Assets | 2.45 | 2.55 | 4.99 | 10.77 | 11.26 | 11.23 | 11.68 | 7.53 | 8.11 | 5.96 | 10.38 | 19.79 |
| Total Assets | 4.98 | 5.08 | 7.71 | 16.63 | 19.71 | 21.07 | 22.72 | 17.97 | 17.61 | 15.33 | 18.75 | 28.05 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -0.06 | 0 | -0.5 | 3.88 | 0.92 | 2.82 | 3.53 | 0.75 | 0.33 | -0.2 | -0.66 | -2.36 |
| Investing | 0 | 0 | -0.19 | -4.23 | -3.41 | -2.4 | -3.15 | -1.53 | -0.94 | -1.59 | -0.7 | -0.9 |
| Financing | 0 | 0.1 | 0.56 | 1.14 | 3.1 | -0.23 | 0.4 | -0.91 | -0.04 | 1.43 | 1.4 | 3.81 |
| Net Cash Flow | -0.06 | 0.09 | -0.14 | 0.79 | 0.61 | 0.2 | 0.78 | -1.69 | -0.65 | -0.36 | 0.04 | 0.56 |
| Free Cash Flow | -0.06 | 0 | -0.69 | -0.35 | -2.49 | 0.42 | 0.38 | -0.78 | -0.61 | -1.79 | -1.36 | -3.26 |
| CFO/OP | 300 | 0 | 1,000 | 359 | 83 | 159 | 103 | 29 | 15 | 6 | -254 | 65 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | — | — | — | 60.48 | 35.01 | 57.58 | 23.01 | 13.61 | 14.7 | 60.28 | 16.57 | 95.24 |
| Inventory Days | — | — | — | 203 | 279 | 88.17 | 107 | 155 | 287 | 124 | 56.09 | 290 |
| Days Payable | — | — | — | 609 | 645 | 312 | 269 | 300 | 310 | 383 | 173 | 530 |
| Cash Conversion Cycle | — | — | — | -346 | -331 | -166 | -139 | -131 | -8.57 | -199 | -101 | -145 |
| Working Capital Days | — | — | — | -59.86 | -71.84 | -56.18 | -48.26 | -36.02 | -0.47 | -116 | -54.23 | -200 |
| ROCE % | 0.81% | 0.2% | 0.19% | 0.66% | 1.56% | 8.4% | 14.34% | 6.13% | 3.67% | -58.39% | -12.06% | -76.6% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Parmax Pharma insights
60 extracted metrics + investor summaries across FY13–FY27.
Documents
Frequently Asked Questions about Parmax Pharma
What does Parmax Pharma Ltd do?
Where is Parmax Pharma Ltd (PARMAX) listed?
Which sector does Parmax Pharma Ltd belong to?
What is the market capitalisation of Parmax Pharma Ltd?
What is the 52-week high and low of Parmax Pharma Ltd?
What is the Return on Equity (ROE) of Parmax Pharma Ltd?
Company Information
Incorporated in 1994, Parmax Pharma Ltd manufactures Bulk Drugs, Drug Intermediates & Speciality Chemicals.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/540359.md for Parmax Pharma Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.